Jingdong Qin

Jingdong Qin has held various leadership roles in the biopharmaceutical industry and academia. Currently serving as Vice President of Process at SPARX BIOPHARMACEUTICAL CORP, responsible for overseeing stable cell line development, medium development, and upstream process optimization. With a background in antibody discovery and pharmacology, Jingdong has played a key role in the development of pre-clinical methods and therapeutic antibody characterization. Previous experience includes research positions at The University of Chicago and Hadassa Medical Centers, focusing on anticancer drug R&D. Jingdong holds a Ph.D. from Peking University.